Jennifer L. Taubert is Executive Vice President and Worldwide Chairman, Innovative Medicine at Johnson & Johnson, the world’s largest healthcare company. She is a member of the Corporation’s Executive Committee and leads the Innovative Medicine Group Operating Committee.
Jennifer is a leader in shaping the global strategy of transformational medical innovation for the Innovative Medicine sector, successfully delivering vital new medicines to prevent, treat and cure complex diseases including cancer, immune-related disorders, serious mental illness, cardiovascular disease, retinal disease and pulmonary hypertension. Under her leadership, J&J Innovative Medicine has become the second-largest pharmaceuticals business globally, with more than $57 billion in worldwide revenue. The company was named No. 1 in the Pharmaceuticals category on Fortune magazine’s “World’s Most Admired Companies” list for 10 consecutive years.
Throughout her career, Jennifer has been committed to improving the lives of people with serious illnesses. Since joining Johnson & Johnson in 2005, her focus has been on reaching increasing numbers of patients around the world with the Company’s transformational therapies. Jennifer led global commercial strategy for the pharmaceuticals business and later, as President, Internal Medicine, built a powerhouse new franchise in cardiovascular and metabolic disease. As Company Group Chairman, The Americas, the business doubled in size, outpacing the industry to become the No. 1 pharmaceutical company in the United States and Canada. Before joining Johnson & Johnson, Jennifer held positions of increasing scope and responsibility at Merck and Allergan.
In recognition of her impact on behalf of patients, Jennifer has been named to Fortune’s “Most Powerful Women” list for the past nine years. She was also named among the “100 Most Influential People in Healthcare” by Modern Healthcare magazine in 2020.
Jennifer is a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) which represents the country’s leading innovative biopharmaceutical research companies, and she is Chair of the Federal Committee. She also serves on the National Academy of Medicine’s Leadership Consortium and on the Advisory Board of the Leonard D. Schaeffer Center for Health Policy and Economics at the University of Southern California. In addition, Jennifer is a member of the Board of Directors of McDonald’s Corporation.
Jennifer received a bachelor’s degree in Pharmacology from the University of California, Santa Barbara and a Master of Business Administration from the Anderson Graduate School of Management, University of California, Los Angeles.
